AMGN - Amgen Inc Stock Price, Fair Value and News

307.40USD+7.10 (+2.36%)Market Closed

Market Summary

USD307.40+7.10

Market Closed

2.36%

AMGN Alerts

1 major insider sales recently.

Big fall in earnings (Y/Y)
Losses in recent quarter

AMGN Stock Price

View Fullscreen

AMGN RSI Chart

AMGN Valuation

Market Cap

164.9B

Price/Earnings (Trailing)

43.82

Price/Sales (Trailing)

5.58

EV/EBITDA

17.83

Price/Free Cashflow

23.23

AMGN Price/Sales (Trailing)

AMGN Profitability

EBT Margin

14.71%

Return on Equity

74.93%

Return on Assets

4.05%

Free Cashflow Yield

4.3%

AMGN Fundamentals

AMGN Revenue

Revenue (TTM)

29.5B

Rev. Growth (Yr)

21.98%

Rev. Growth (Qtr)

-9.14%

AMGN Earnings

Earnings (TTM)

3.8B

Earnings Growth (Yr)

-103.98%

Earnings Growth (Qtr)

-114.73%

Breaking Down AMGN Revenue

Last 7 days

10.8%

Last 30 days

14.2%

Last 90 days

4.3%

Trailing 12 Months

31.1%

How does AMGN drawdown profile look like?

AMGN Financial Health

Current Ratio

1.42

Debt/Equity

11.96

Debt/Cashflow

0.13

AMGN Investor Care

Dividend Yield

2.81%

Dividend/Share (TTM)

8.64

Shares Dilution (1Y)

0.39%

Diluted EPS (TTM)

7.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	29.5B	0	0	0
2023	26.2B	26.6B	26.8B	28.2B
2022	26.3B	26.4B	26.3B	26.3B
2021	25.2B	25.5B	25.8B	26.0B
2020	24.0B	24.3B	25.0B	25.4B
2019	23.8B	23.6B	23.4B	23.4B
2018	22.9B	23.2B	23.3B	23.7B
2017	22.9B	23.1B	23.0B	22.8B
2016	22.2B	22.5B	22.6B	23.0B
2015	20.6B	20.8B	21.5B	21.7B
2014	19.0B	19.5B	19.7B	20.1B
2013	17.5B	17.7B	18.1B	18.7B
2012	15.9B	16.4B	16.8B	17.3B
2011	15.2B	15.3B	15.4B	15.6B
2010	14.9B	15.0B	15.0B	15.1B
2009	14.7B	14.6B	14.6B	14.6B
2008	0	14.8B	14.9B	15.0B
2007	0	0	0	14.8B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amgen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	drake michael v	acquired	-	-	116	-
May 07, 2024	holley charles m	acquired	-	-	141	-
May 07, 2024	ishrak omar	acquired	-	-	116	-
May 05, 2024	reese david m	sold (taxes)	-197,047	311	-633	evp & chief technology officer
May 05, 2024	bradway robert a	sold (taxes)	-691,064	311	-2,220	chairman, ceo and president
May 05, 2024	miller derek	sold (taxes)	-24,280	311	-78.00	svp, human resources
May 05, 2024	santos esteban	sold (taxes)	-192,066	311	-617	evp, operations
May 05, 2024	graham jonathan p	sold (taxes)	-196,735	311	-632	evp & gen. counsel & secy.
May 05, 2024	khosla rachna	sold (taxes)	-12,762	311	-41.00	svp, business development
May 05, 2024	griffith peter h.	sold (taxes)	-201,716	311	-648	evp & cfo

Which funds bought or sold AMGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	CIM INVESTMENT MANAGEMENT INC	unchanged	-	-9,417	723,594	0.22%
May 07, 2024	CHILTON CAPITAL MANAGEMENT LLC	added	5.91	836,524	19,224,300	0.91%
May 07, 2024	Empowered Funds, LLC	added	63.69	7,020,700	18,420,000	0.17%
May 07, 2024	BEACON FINANCIAL GROUP	reduced	-16.27	-735,168	3,502,550	0.40%
May 07, 2024	Allen Investment Management, LLC	unchanged	-	-18,807	1,445,200	0.02%
May 07, 2024	WestEnd Advisors, LLC	added	12.5	255	2,559	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-40.88	-36,831,700	51,631,400	0.01%
May 07, 2024	WILBANKS SMITH & THOMAS ASSET MANAGEMENT LLC	reduced	-3.51	-187,506	3,762,820	0.10%
May 07, 2024	Arizona State Retirement System	added	2.05	321,163	43,665,600	0.30%
May 07, 2024	WINDWARD CAPITAL MANAGEMENT CO /CA	reduced	-0.33	-103,000	6,266,000	0.52%

Are Funds Buying or Selling AMGN?

Are funds buying AMGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMGN

No. of Funds

Unveiling Amgen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.16%	49,036,311	SC 13G/A
Jan 30, 2024	state street corp	5.52%	29,543,705	SC 13G/A
Jan 25, 2024	blackrock inc.	8.9%	47,811,356	SC 13G/A
Feb 09, 2023	vanguard group inc	9.01%	48,065,139	SC 13G/A
Feb 07, 2023	blackrock inc.	9.1%	48,513,079	SC 13G/A
Feb 06, 2023	state street corp	5.58%	29,760,088	SC 13G/A
Feb 11, 2022	capital research global investors	3.9%	22,157,906	SC 13G/A
Feb 10, 2022	state street corp	5.37%	30,221,708	SC 13G/A
Feb 09, 2022	vanguard group inc	8.28%	46,661,009	SC 13G/A
Feb 01, 2022	blackrock inc.	8.9%	50,046,345	SC 13G/A

Recent SEC filings of Amgen Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading

Peers (Alternatives to Amgen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	358.5B	85.6B	-1.74%	-7.51%	9.32	4.19	5.68%	202.39%
MRK	328.0B	61.4B	2.34%	10.30%	142.26	5.34	6.11%	-82.30%
AMGN	164.9B	29.5B	14.19%	31.13%	43.82	5.58	12.76%	-52.47%
PFE	160.3B	57.8B	6.40%	-25.71%	127.84	2.77	76.51%	-86.81%
GILD	80.9B	27.4B	-6.51%	-17.64%	166.89	2.95	1.51%	-91.32%
TEVA	17.8B	16.0B	10.77%	72.86%	-36.03	1.11	7.23%	71.10%
MID-CAP
PRGO	4.2B	4.6B	-2.02%	-10.81%	-550.77	0.93	-0.06%	94.55%
ALKS	4.1B	1.7B	-7.02%	-22.02%	9.39	2.36	54.01%	364.56%
BHC	2.6B	9.0B	-27.55%	19.80%	-5.66	0.29	10.01%	-27.45%
AMPH	2.0B	644.4M	2.87%	15.89%	14.77	3.15	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-25.10%	-28.68%	-4.27	2.02	24.65%	80.36%
TXMD	23.3M	1.3M	-6.48%	-47.40%	-2.27	17.89	-98.14%	-109.18%
ACRX	17.5M	-	-11.21%	50.12%	-0.95	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	5.13%	-93.31%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Amgen Inc News

Latest updates

Amgen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-9.1%	7,447	8,196	6,903	6,986	6,105	6,839	6,652	6,594	6,238	6,846	6,706	6,526	5,901	6,634	6,423	6,206	6,161	6,197	5,737	5,871	5,557
Costs and Expenses	-6.8%	6,456	6,925	4,882	4,302	4,184	4,609	3,992	4,418	3,738	4,542	4,328	5,698	3,772	4,626	3,970	3,883	3,806	4,149	3,261	3,193	3,085
S&GA Expenses	-20.5%	1,808	2,274	1,353	1,294	1,258	1,572	1,287	1,327	1,228	1,425	1,305	1,384	1,254	1,773	1,346	1,295	1,316	1,513	1,223	1,260	1,154
EBITDA Margin	-22.2%	0.41*	0.53*	0.55*	0.56*	0.54*	0.46*	0.47*	0.46*	0.42*	0.43*	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0.4%	824	821	759	752	543	415	368	328	295	335	296	281	285	318	302	296	346	301	313	332	343
Income Taxes	-47.1%	45.00	85.00	217	235	601	132	249	214	199	232	271	94.00	211	262	185	227	195	280	309	385	322
Earnings Before Taxes	-108.0%	-68.00	852	1,947	1,614	3,442	1,748	2,392	1,531	1,675	2,131	2,155	558	1,857	1,877	2,206	2,030	2,020	1,983	2,277	2,564	2,314
EBT Margin	-47.2%	0.15*	0.28*	0.33*	0.35*	0.35*	0.28*	0.29*	0.28*	0.25*	0.26*	-	-	-	-	-	-	-	-	-	-	-
Net Income	-114.7%	-113	767	1,730	1,379	2,841	1,616	2,143	1,317	1,476	1,899	1,884	464	1,646	1,615	2,021	1,803	1,825	1,703	1,968	2,179	1,992
Net Income Margin	-46.5%	0.13*	0.24*	0.28*	0.30*	0.30*	0.25*	0.26*	0.25*	0.22*	0.23*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	58.8%	459	289	2,512	3,838	720	2,309	2,818	1,684	1,974	2,521	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.3%	92,980	97,154	90,534	90,269	88,720	65,121	63,700	59,294	59,196	61,165	64,993	59,773	62,539	62,948	64,637	65,011	61,669	59,707	59,535	59,373	63,997
Current Assets	-7.6%	28,029	30,332	48,477	47,380	44,703	22,186	24,062	19,322	18,520	19,385	24,380	19,099	21,299	21,144	22,661	22,895	18,813	18,440	31,051	30,746	35,151
Cash Equivalents	-11.3%	9,708	10,944	34,700	34,200	31,600	7,629	9,502	5,203	6,528	7,989	11,969	6,630	6,112	6,266	9,087	9,145	7,687	6,037	11,415	5,525	7,358
Inventory	-8.3%	8,724	9,518	5,026	4,978	5,011	4,930	4,757	4,554	4,411	4,086	4,152	4,115	4,017	3,893	3,942	3,840	3,682	3,584	3,243	3,176	3,016
Net PPE	1.0%	6,002	5,941	5,563	5,532	5,460	5,427	5,188	5,158	5,142	5,184	4,982	4,906	4,855	4,889	4,816	4,843	4,879	4,928	4,901	4,882	4,892
Goodwill	-0.3%	18,570	18,629	3,111	15,531	15,531	15,529	14,845	14,865	14,897	14,890	14,665	14,676	14,673	14,689	14,674	14,678	14,683	14,703	14,705	26.00	14,692
Current Liabilities	7.2%	19,714	18,392	16,954	17,097	14,215	15,687	14,331	12,618	12,886	12,184	14,842	14,585	12,869	11,653	9,953	10,523	11,827	12,835	10,737	10,622	12,706
Long Term Debt	-4.9%	60,061	63,170	59,040	59,377	60,761	37,354	37,161	35,705	36,010	33,222	33,291	28,458	31,129	32,895	34,196	34,133	30,008	26,950	27,742	27,798	29,319
LT Debt, Current	174.4%	3,959	1,443	1,428	2,167	834	1,591	1,543	817	844	87.00	4,288	4,324	1,556	91.00	91.00	91.00	1,840	2,953	2,049	2,816	3,705
LT Debt, Non Current	-100.0%	-	63,170	59,040	59,377	60,761	37,354	37,161	35,705	36,010	33,222	33,291	28,458	31,129	32,895	34,196	34,133	30,008	26,950	27,742	27,798	29,319
Shareholder's Equity	-19.4%	5,022	6,232	7,656	6,781	5,348	3,661	3,653	2,419	916	6,700	8,217	8,247	9,334	9,409	10,959	10,659	9,485	9,673	10,927	10,794	10,832
Retained Earnings	-5.0%	-27,870	-26,549	-24,971	-25,540	-26,919	-28,622	-28,066	-28,252	-29,568	-24,600	-22,964	-22,762	-21,639	-21,408	-19,851	-20,168	-21,378	-21,330	-20,136	-20,054	-19,895
Shares Outstanding	0.2%	536	535	535	535	534	534	539	535	548	570	567	575	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	118,556	-	-	-	129,940	-	-	-	137,531	-	-	-	138,057	-	-	-	110,809	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	28.1%	689	538	2,760	4,109	1,064	2,649	2,978	1,930	2,164	2,808	2,418	1,931	2,104	2,153	3,368	2,842	2,134	2,514	3,377	1,414	1,845
Share Based Compensation	-	103	-	-	-	47.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Investing	99.2%	-217	-27,089	-262	-211	1,358	-3,473	-267	-2,193	-111	-230	73.00	1,209	-319	-1,384	-1,628	-2,159	-230	-5,963	5,372	2,745	3,555
Cashflow From Financing	-162.0%	-1,708	2,754	-2,005	-1,210	21,509	-1,049	1,588	-1,062	-3,514	-6,558	2,848	-2,622	-1,939	-3,590	-1,798	775	-254	-1,929	-2,859	-5,992	-4,987
Dividend Payments	6.0%	1,208	1,140	1,140	1,139	1,137	1,040	1,038	1,038	1,080	990	999	1,008	1,016	932	936	942	945	860	868	880	901
Buy Backs	-	-	-	-	-	-	900	-	50.00	6,310	1,446	1,069	1,592	865	1,208	752	591	933	1,123	1,170	2,349	3,031

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AMGN Income Statement

2024-03-31

Condensed Consolidated Statements of (Loss) Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 7,447	$ 6,105
Operating expenses:
Cost of sales	3,200	1,720
Research and development	1,343	1,058
Selling, general and administrative	1,808	1,258
Other	105	148
Total operating expenses	6,456	4,184
Operating income	991	1,921
Other income (expense):
Interest expense, net	(824)	(543)
Other (expense) income, net	(235)	2,064
(Loss) income before income taxes	(68)	3,442
Provision for income taxes	45	601
Net (loss) income	$ (113)	$ 2,841
(Loss) earnings per share:
Basic (in usd per share)	$ (0.21)	$ 5.32
Diluted (in usd per share)	$ (0.21)	$ 5.28
Shares used in calculation of (loss) earnings per share:
Basic (in shares)	536	534
Diluted (in shares)	536	538
Product sales
Revenues:
Total revenues	$ 7,118	$ 5,846
Other revenues
Revenues:
Total revenues	$ 329	$ 259

AMGN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 9,708	$ 10,944
Trade receivables, net	6,776	7,268
Inventories	8,724	9,518
Other current assets	2,821	2,602
Total current assets	28,029	30,332
Property, plant and equipment, net	6,002	5,941
Intangible assets, net	31,372	32,641
Goodwill	18,570	18,629
Other noncurrent assets	9,007	9,611
Total assets	92,980	97,154
Current liabilities:
Accounts payable	1,628	1,590
Accrued liabilities	14,127	15,359
Current portion of long-term debt	3,959	1,443
Total current liabilities	19,714	18,392
Long-term debt	60,061	63,170
Long-term deferred tax liabilities	1,862	2,354
Long-term tax liabilities	3,964	4,680
Other noncurrent liabilities	2,357	2,326
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—536.4 shares in 2024 and 535.4 shares in 2023	33,082	33,070
Accumulated deficit	(27,870)	(26,549)
Accumulated other comprehensive loss	(190)	(289)
Total stockholders’ equity	5,022	6,232
Total liabilities and stockholders’ equity	$ 92,980	$ 97,154

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃƒÂ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

CEO	Mr. Robert A. Bradway
WEBSITE	amgen.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	25200

Amgen Inc Frequently Asked Questions

What is the ticker symbol for Amgen Inc? What does AMGN stand for in stocks?

AMGN is the stock ticker symbol of Amgen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amgen Inc (AMGN)?

As of Wed May 08 2024, market cap of Amgen Inc is 164.9 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers. The fair value of Amgen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amgen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amgen Inc a good stock to buy?

The fair value guage provides a quick view whether AMGN is over valued or under valued. Whether Amgen Inc is cheap or expensive depends on the assumptions which impact Amgen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMGN.

What is Amgen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, AMGN's PE ratio (Price to Earnings) is 43.82 and Price to Sales (PS) ratio is 5.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amgen Inc's stock?

In the past 10 years, Amgen Inc has provided 0.135 (multiply by 100 for percentage) rate of return.